M Michelle Berrey, President of Intercept Pharmaceuticals, appears to have filed an empty initial statement of beneficial ownership. This form is usually filed as a prelude to a company officer either receiving options or buying company shares, so there may be more to come from Berrey.
Here is the filing.
To get notified when Intercept Pharmaceuticals makes a similar move, sign up!
Other recent filings from the company include the following:
Intercept Pharmaceuticals Reports Second Quarter 2022 Financial Results And Provides Business Update - Aug. 3, 2022
Intercept Pharmaceuticals Just Filed Its Quarterly Report: 14. Net Loss Per ... - Aug. 3, 2022
Intercept Pharmaceuticals's General Counsel just disposed of 771 shares - Aug. 3, 2022
On July - July 26, 2022
Intercept Pharmaceuticals's Chief Qual. Officer & SVP Ops. just disposed of 436 shares - July 13, 2022
